Evonik Evonik

X
[{"orgOrder":0,"company":"Excivion","sponsor":"CPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CPI Partners with Excivion to Optimise and Scale up Production of Safe and Effective Zika Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Excivion

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Excivion has partnered with CPI to draw upon the company’s extensive experience in the optimisation and scale-up of biologics manufacturing processes to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX.

            Lead Product(s): Zika-HX antigen

            Therapeutic Area: Infections and Infectious Diseases Product Name: Zika vaccine

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: CPI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY